Back to top
more

AstraZeneca (AZN)

(Delayed Data from NSDQ)

$73.55 USD

73.55
4,986,256

-1.02 (-1.37%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $73.54 -0.01 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (142 out of 244)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Sweta Killa headshot

Biotech ETF (SBIO) Hits a New 52-Week High

by Sweta Killa

This biotech ETF hits a new 52-week high. Are more gains in store for this ETF?

Zacks Equity Research

AstraZeneca (AZN) Stock Down on $39B Offer to Buy Alexion

by Zacks Equity Research

AstraZeneca (AZN) agrees to buy U.S. drugmaker Alexion Pharmaceuticals for $39 billion in its largest M&A deal ever.

Kinjel Shah headshot

COVID-19 Vaccine Race Heats Up as Pfizer Gets Emergency Nod

by Kinjel Shah

FDA grants emergency use approval to Pfizer (PFE)/BioNTech's (BNTX) COVID-19 vaccine candidate.

Sweta Killa headshot

5 Energy ETFs Making the Most of the Oil Rally

by Sweta Killa

After registering the best month ever, the energy sector continued its bullish trend on vaccine optimism,

Zacks Equity Research

Pfizer/BioNTech COVID-19 Vaccine Gets FDA Panel's Backing

by Zacks Equity Research

An FDA panel recommends granting approval for emergency use of Pfizer's (PFE)/BioNTech's (BNTX) COVID-19 vaccine

Zacks Equity Research

Moderna (MRNA) Starts COVID-19 Vaccine Study in Adolescents

by Zacks Equity Research

Moderna (MRNA) initiates development of its coronavirus vaccine candidate, mRNA-1273, in adolescent patients in a phase II/III study.

Sweta Killa headshot

Inflation to Pick Up in 2021: Bet on TIPS ETFs

by Sweta Killa

The expectation for an uptick in inflation has led to investors' flocking to Treasury Inflation Protected Securities (TIPS) ETFs.

Sweta Killa headshot

Emerging Markets Hit Record High: 5 Top-Performing ETFs YTD

by Sweta Killa

While many emerging market ETFs have been performing remarkably well, we highlight five funds that are leading the space from a year-to-date basis.

Zacks Equity Research

Pfizer/BioNTech COVID-19 Vaccine Raises New Safety Concerns

by Zacks Equity Research

The Bell's palsy related side-effects are not alarming enough to preclude FDA from granting emergency approval to Pfizer (PFE)/BioNTech's (BNTX) COVID-19 vaccine.

Zacks Equity Research

Lilly's (LLY) Tirzepatide Meets Endpoints in Late-Stage Study

by Zacks Equity Research

Lilly's (LLY) tirzepatide demonstrates superiority in improving blood sugar levels and reducing body-weight compared to placebo in a phase III study evaluating in type 2 diabetes patients.

Sweta Killa headshot

5 Sector ETFs Still At Cheap Prices Amid Peak Market

by Sweta Killa

Though many sectors are hitting new highs amid the peak market, some funds are still down from a year-to-date look and are due to climb in the coming weeks.

Sweta Killa headshot

Equal-Weight ETFs Leading Latest Market Rally: Here's Why

by Sweta Killa

While the rally has been broad-based, equal-weighted ETFs are outperforming their cap-weighted peers.

Zacks Equity Research

IPO Market Set to Thrive in December

by Zacks Equity Research

IPO Market Set to Thrive in December

Zacks Equity Research

Glaxo's (GSK) Nucala Filing for Nasal Polyps Accepted by FDA

by Zacks Equity Research

The FDA accepts Glaxo's (GSK) regulatory filing for Nucala to treat patients with chronic rhinosinusitis with nasal polyps. The drug is already approved for three other indications.

Mark Vickery headshot

DoorDash IPOs at $102, Vaccine Rally Cooling

by Mark Vickery

DoorDash is pricing its Initial Public Offering at $102 per share, for a valuation of $38.7 billion.

Neena Mishra headshot

Should You Buy Oil & Gas ETFs Now?

by Neena Mishra

Energy ETFs rebounded strongly in November but are still down significantly for the year

Zacks Equity Research

Moderna (MRNA) to Supply More Doses of COVID-19 Vaccine to Canada

by Zacks Equity Research

Moderna (MRNA) announces deal to supply 20 million additional doses of its COVID-19 vaccine candidate, mRNA-1273, to the Canadian Government, upon potential approval. The total tally is now 40 million doses.

Sweta Killa headshot

Small-Cap ETFs Face Off: IWM Vs. IJR

by Sweta Killa

Small-cap companies are closely tied to the U.S. economy and are thus poised to outperform when the economy improves.

Zacks Equity Research

Pfizer (PFE) Up 14% in 3 Months on COVID-19 Vaccine Progress

by Zacks Equity Research

Pfizer (PFE) and BioNTech's (BNTX) COVID-19 vaccine candidate is now approved for emergency use in United Kingdom and Bahrain.

Zacks Equity Research

Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?

by Zacks Equity Research

Sector ETF report for PPH

Sweta Killa headshot

Holiday Shopping Shifts to E-Commerce: ETFs to Tap

by Sweta Killa

Given the digital shopping boom, stocks in the Internet and e-commerce retail space look poised for solid gains this holiday season.

Zacks Equity Research

J&J (JNJ) Files BLA for Lung Cancer Candidate Amivantamab

by Zacks Equity Research

J&J (JNJ) files a BLA to the FDA for amivantamab for the treatment metastatic non-small cell lung cancer with EGFR Exon 20 insertion mutations.

Kinjel Shah headshot

Pharma Stock Roundup: Approval of PFE/BNTX Coronavirus Vaccine in UK, Other Updates

by Kinjel Shah

Pfizer (PFE) COVID-19 vaccine gets approval for emergency use in the United Kingdom while Roche's (RHHBY) Xolair gets FDA nod for new indication.

John Blank headshot

The Vaccines Are Here. Are We Out of the Woods Now?

by John Blank

It almost seems like we are just an appointment at the doctor's office away from opening up our economy again.

Sweta Killa headshot

Stocks to Track in December as Markets Peak

by Sweta Killa

December is likely to be filled with events or stock/sector specific news that could provide a boost to the stocks.